Original news and analysis on international IP policy
Despite the Trans-Pacific Partnership (TPP) being - to all-intents-and-purposes - dead in the water, pursuit of some of the most egregious objectives of the corporate interests driving the TPP agenda rolls on. Pharma is persisting in its push for countries to adopt not just TRIPS-Plus, but in some cases even TPP-Plus intellectual property rules - presumably groundwork for the later emergence of a ‘son-of-TPP’ agreement, three authors write.
The winners of the 2016 Patents for Humanity Award of the United States Patent and Trademark Office this year are recognised for providing global disease solutions. The inventions relate to malaria, vaccines, a life-threatening pregnancy complication, and meningitis.
Thomas Cueni of Switzerland has been named the next director general of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Geneva-based organisation which represents the global research-based pharma industry.
Pfizer Board Chairman and CEO Ian Read has been elected as the next president of the Geneva-based International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), a two-year role.
The UN World Health Organization this week clarified that the possibility exists for the WHO Executive Board to discuss a recently released report from a UN Secretary General-appointed panel that makes recommendations for improving global access to medicines.
The government of Dominica has deposited its instrument of acceptance of the 2005 so-called "paragraph 6" amendment to international intellectual property trade rules aimed at making it easier for countries to export affordable medical products to developing countries. Dominica's signing brings the number of signers to 65 percent of WTO members, according to the WTO. Two-thirds of WTO members must accept it for the amendment to go into effect, but it is unclear exactly how many members that represents. It appears that two or three more members will tip the scale.
For Roberto Azevêdo, director general of the World Trade Organization, an amendment to the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement that affects access to pharmaceuticals for developing countries remains a priority of the WTO.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that its director general is stepping down at the end of January.
The World Health Organization has published two advanced documents to be presented at the organisation’s Executive Board meeting in January. One relates to the review of the WHO mechanism for pandemic influenza preparedness, and the other to the public health implications of the implementation of an international treaty on genetic resources.
United Nations Secretary-General Ban Ki-moon today issued a message praising the "milestone" report of a High-Level Panel on access to medicines he set up a year ago to address the continuing problem of medicines prices being too high for many in the world to afford, and the lack of access to quality medicines for many. In his message, he called on governments to review the report and its recommendations, and to chart a way forward to address the problem of lack of access to medicines and health technologies.
Candidates from around the world vying to be the next director general of the World Health Organization in recent weeks have presented their views to member states on a range of public health issues. Two of the six candidates answered a question put to them by Intellectual Property Watch relating to medicines prices, innovation and intellectual property. Here are their answers.
A new report from UNAIDS shows that antiretroviral therapy is now accessed by 18.2 million people living with HIV, and fewer people are dying from the virus infection. However, there is stalled progress on HIV prevention among adults, and growing antiretroviral drug resistance among people living with HIV over a long time.